Emergent BioSolutions (FRA:ER4) Cyclically Adjusted FCF per Share: €0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ER4 Emergent BioSolutions Inc FRA:ER4
61 GF Score
Price €6.54
GF Value €4.15
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Emergent BioSolutions Cyclically Adjusted FCF per Share?

Emergent BioSolutions FRA:ER4 +2.19% 61 Cyclically Adjusted FCF per Share is €0.00 as of Jun. 2026. GuruFocus rates FRA:ER4 with a GF Score™ of 61/100 and a GF Value™ of €4.15 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Emergent BioSolutions's adjusted free cash flow per share for the three months ended in Jun. 2026 was €0.908. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Emergent BioSolutions's average Cyclically Adjusted FCF Growth Rate was 1.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -11.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -10.60% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 13.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Emergent BioSolutions was 43.60% per year. The lowest was -24.80% per year. And the median was 13.25% per year.

As of today (2026-08-06), Emergent BioSolutions's current stock price is €6.535. Emergent BioSolutions's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €0.00. Emergent BioSolutions's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Emergent BioSolutions was 134.77. The lowest was 1.81. And the median was 47.49.


Emergent BioSolutions  (FRA:ER4) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Emergent BioSolutions was 134.77. The lowest was 1.81. And the median was 47.49.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Emergent BioSolutions Cyclically Adjusted FCF per Share Related Terms


Emergent BioSolutions Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Emergent BioSolutions's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emergent BioSolutions Cyclically Adjusted FCF per Share Chart

Emergent BioSolutions Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.54 1.43 0.79 0.57 0.90

Emergent BioSolutions Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 0.79 0.90 0.82 0.00

FRA:ER4 vs EOLS, ELTP, AKBA: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emergent BioSolutions Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Cyclically Adjusted Price-to-FCF falls into.


FRA:ER4
61GF Score
Emergent BioSolutions Inc FRA:ER4
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emergent BioSolutions Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Emergent BioSolutions's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.908/333.9520*333.9520
=0.908

Current CPI (Jun. 2026) = 333.9520.

Emergent BioSolutions Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 0.182 241.428 0.252
201612 -0.609 241.432 -0.842
201703 0.402 243.801 0.551
201706 0.794 244.955 1.082
201709 0.368 246.819 0.498
201712 1.080 246.524 1.463
201803 -0.206 249.554 -0.276
201806 0.351 251.989 0.465
201809 2.461 252.439 3.256
201812 -3.154 251.233 -4.192
201903 1.442 254.202 1.894
201906 -0.858 256.143 -1.119
201909 -0.319 256.759 -0.415
201912 1.469 256.974 1.909
202003 0.585 258.115 0.757
202006 1.540 257.797 1.995
202009 0.930 260.280 1.193
202012 3.160 260.474 4.051
202103 -0.786 264.877 -0.991
202106 -1.486 271.696 -1.826
202109 -0.609 274.310 -0.741
202112 4.670 278.802 5.594
202203 -1.245 287.504 -1.446
202206 -0.903 296.311 -1.018
202209 -2.063 296.808 -2.321
202212 1.312 296.797 1.476
202303 -3.704 301.836 -4.098
202306 -2.310 305.109 -2.528
202309 0.857 307.789 0.930
202312 0.364 306.746 0.396
202403 -1.294 312.332 -1.384
202406 0.758 314.175 0.806
202409 2.397 315.301 2.539
202412 -1.438 315.605 -1.522
202503 -0.239 319.799 -0.250
202506 1.656 322.561 1.714
202509 -0.086 324.800 -0.088
202512 1.112 324.054 1.146
202603 -0.554 330.213 -0.560
202606 0.908 333.952 0.908

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €0.00 mean?
Emergent BioSolutions (FRA:ER4) has a Cyclically Adjusted FCF per Share of €0.00 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Emergent BioSolutions and its competitors.
Is Emergent BioSolutions' Cyclically Adjusted FCF per Share too high?
Emergent BioSolutions' current Cyclically Adjusted FCF per Share is €0.00. Overall, Emergent BioSolutions has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Cyclically Adjusted FCF per Share compare to EOLS and ELTP?
Emergent BioSolutions' Cyclically Adjusted FCF per Share of €0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Emergent BioSolutions and its competitors. Emergent BioSolutions's current Cyclically Adjusted FCF per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (FRA:ER4) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.15, compared to a current price of €6.54 — trading 57.5% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €0.00. Emergent BioSolutions' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Emergent BioSolutions (FRA:ER4), the current Cyclically Adjusted FCF per Share is €0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Emergent BioSolutions (FRA:ER4) Overvalued in 2026?

Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued. The current stock price of €6.54 is trading 57.5% above its estimated GF Value™ of €4.15. GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.

Key valuation signals for FRA:ER4:

  • Cyclically Adjusted FCF per Share: €0.00
  • GF Value™: €4.15 vs. price of €6.54 (57.5% above fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the FRA:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Emergent BioSolutions Business Description

Other Exchanges EBS:USA0IGA:UKER4:Germany
Address 300 Professional Drive, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
61GF Score

Get the complete analysis for FRA:ER4

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.54
Price
€4.15
GF Value